MODULE 10: PHARMACOVIGILANCE
of drug development, from initial research and development activities to final consumer use and is commonly divided into two stages (Fig. 10.1): pre-marketing surveillance: adverse drug reactions from preclinical screening and Phase I, II and III clinical trials; and post-marketing surveillance: adverse drug
Download MODULE 10: PHARMACOVIGILANCE
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
Ricerca Preclinical Primer - UC Davis Health
health.ucdavis.eduPreclinical Development • Pharmacology • Metabolism studies • Animal models • Pharmacokinetics • Toxicology (IND & beyond) Chemical Services • cGMP synthesis (grams to kilos) • Process chemistry • Analytical chemistry • Process development & engineering DMPK • Bioanalytical method development and validation
Guideline on Development and Manufacture of Lentiviral …
www.ema.europa.euthe current Note for Guidance (NfG) on the quality, preclinical and clinical aspects of gene transfer medicinal products, CPMP/BWP/3088/99). This guideline describes quality aspects and non-clinical testing that are in general relevant for LV that are intended for ex vivo or in vivo application. However,
S6(R1) Step 5 Preclinical safety evaluation of ...
www.ema.europa.eucase, science-based approach to preclinical safety evaluation needed to support clinical development and marketing authorisation. In this rapidly evolving scientific area, there is a need for common understanding and continuing dialogue among the regions.
Drug Discovery and Preclinical Development
www.lehigh.edu*All R&D costs (basic research and preclinical development) prior to initiation of clinical testing ** Based on a 5-year shift and prior growth rates for the preclinical and clinical periods. DiMasi and Grabowski (2007) II. The Research & Developppment Landscape.
Basic Overview of Preclinical Toxicology in Drug Development
www.uab.edu•Development of proper preclinical models which can efficiently predict drug behavior in humans is essential prior to testing a drug in a human subject. •The FDA and other regulatory agencies are more and more requiring Sponsors to provide data to support selection of the specific species (and even strains) used to support testing of new drugs.